Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease
NCT00500500
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
40
Enrollment
INDUSTRY
Sponsor class
Stopped
Inability to recruit sufficient number of patients
Conditions
Alzheimer Disease
Interventions
DRUG:
EGb 761® (Tanakan®)
Sponsor
Ipsen